Comparison of treatment outcomes of pelvis external radiotherapy with and without vaginal brachytherapy for cervical cancer patients with positive or close vaginal resected margins [0.03%]
阳性或接近阴道切除边缘的宫颈癌患者接受单纯盆腔外放射治疗和联合阴道近距离放疗的疗效比较
Yun Hee Lee,Yeon Sil Kim,Kyu Hye Choi et al.
Yun Hee Lee et al.
Background: We evaluated whether there is a difference in the local recurrence and survival after pelvic external radiotherapy (ERT) with and without boost vaginal brachytherapy (VB) in cervical cancer patients with posit...
Fumihiko Urabe,Takahiro Kimura,Hiroshi Sasaki et al.
Fumihiko Urabe et al.
Background: Prostate-specific antigen (PSA) bounce after definitive radiotherapy has been reported as a predictor of improved biochemical recurrence-free survival (BCRFS). We revisited this phenomenon to confirm its clini...
Systematic study on expression and prognosis of E2Fs in human colorectal cancer [0.03%]
人结直肠癌中E2Fs的表达和预后的系统研究
Yating Ma,Shijian Wang,Jinfeng Bao et al.
Yating Ma et al.
Background: E2Fs are important components of transcription factors and play key roles in occurrence or advancement of various cancers, but the expression and exact roles of each E2F in colorectal cancer (CRC) are rarely k...
HER2-low breast cancer could be associated with an increased risk of brain metastasis [0.03%]
HER2低表达乳腺癌可能与脑转移风险增加相关
Deniz Can Guven,Mehmet Burak Kaya,Burak Fedai et al.
Deniz Can Guven et al.
Purpose: The HER2-low breast cancer is a newly recognized entity with the clinical characteristics is yet to be defined. We hypothesized that HER2-low breast cancer could lead to an increased rate of brain metastases in p...
Correction to: An analysis of tumor-related skin temperature differences in malignant soft-tissue tumors [0.03%]
校正：恶性软组织肿瘤相关的皮肤温度差异分析
Akiyoshi Shimatani,Manabu Hoshi,Naoto Oebisu et al.
Akiyoshi Shimatani et al.
Ashita Gadwal,Anupama Modi,Manoj Khokhar et al.
Ashita Gadwal et al.
Galectins are defined as the glycan-binding protein containing either one or two carbohydrate-binding domains and participate in various biological functions such as developmental processes, vascularisation programs, cell migration, and imm...
Prospective feasibility study of neoadjuvant dose-dense paclitaxel plus carboplatin with bevacizumab therapy followed by interval debulking surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer patients [0.03%]
新辅助密集紫杉醇联合卡铂和贝伐珠单抗治疗继以间歇性减瘤手术治疗晚期卵巢，输卵管和原发腹膜癌患者的前瞻性可行性研究
Naomi Iwasa-Inoue,Hiroyuki Nomura,Fumio Kataoka et al.
Naomi Iwasa-Inoue et al.
Background: This study aimed to investigate the clinical benefit of dose-dense paclitaxel plus carboplatin (TC) with bevacizumab therapy for advanced ovarian, fallopian tube, and primary peritoneal cancer patients in the ...
Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B) [0.03%]
奥希替尼治疗一代和二代EGFR-TKI失败后伴有T790M突变的晚期非小细胞肺癌的体能状态差的患者(NEJ032B)
Yukari Tsubata,Kana Watanabe,Ryota Saito et al.
Yukari Tsubata et al.
Background: Osimertinib is effective in patients with T790M mutation-positive advanced non-small-cell lung cancer (NSCLC) resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). However, it...
The Real-World status and risk factors for a poor prognosis in elderly patients with primary central nervous system malignant lymphomas: a multicenter, retrospective cohort study of the Tohoku Brain Tumor Study Group [0.03%]
老年原发性中枢神经系统恶性淋巴瘤患者的现实状况及预后不良的危险因素：东日本脑肿瘤研究组的多中心回顾队列研究
Kenichiro Asano,Yoji Yamashita,Takahiro Ono et al.
Kenichiro Asano et al.
Background: Elderly patients with primary central nervous system malignant lymphoma (EL-PCNSL) may not be given sufficient treatment due to their poor pre-treatment Karnofsky Performance Status (KPS) and comorbidities. Th...
Tadashi Kumamoto,Fumito Yamazaki,Yoshiko Nakano et al.
Tadashi Kumamoto et al.
Li-Fraumeni syndrome (LFS) is a hereditary tumor that exhibits autosomal dominant inheritance. LFS develops in individuals with a pathogenic germline variant of the cancer-suppressor gene, TP53 (individuals with TP53 pathogenic variant). Th...